Fever and a low neutrophil count on clozapine
A 29-year-old Kuwaiti man with DSM-5 schizophrenia diagnosed at 21 has persistent auditory hallucinations and persecutory delusions despite trials of risperidone 6 mg, olanzapine 20 mg and haloperidol decanoate 200 mg monthly, each for at least 8 weeks with documented adherence. Clozapine was started 12 weeks ago and titrated to 300 mg nightly; his PANSS has fallen from 98 to 68 and he has returned to part-time work. He smokes 30 cigarettes daily and wants to stop next week using nicotine replacement. Today he reports a sore throat and feels feverish at 38.2°C. Investigations show WBC 4.8 ×10^9/L, absolute neutrophil count 1.4 ×10^9/L (pre-clozapine baseline 2.1), CRP 45 mg/L, weight up 7 kg, and he has not opened his bowels for 4 days. He takes no other medication.
1. Interpret the ANC and fever. What is your immediate action, and how do you distinguish clozapine-induced neutropenia from benign ethnic neutropenia and from sepsis?
Read the worked answer
An ANC of 1.4 ×10^9/L is below the usual 1.5 threshold, so under any clozapine monitoring programme this is a red result. With fever and sore throat, this is agranulocytosis until proven otherwise: stop clozapine, repeat the FBC with differential and blood film urgently, take throat swab, urine and blood cultures, examine the chest, and involve haematology. If the ANC falls below 0.5 or there is sepsis, granulocyte colony-stimulating factor and reverse-barrier precautions are needed.
Benign ethnic neutropenia is common in people of African and Middle Eastern ancestry and is characterised by a chronically low ANC (often 1.0–1.5) with normal lymphocyte and monocyte counts and no increased infection risk. The key clue here is the pre-clozapine baseline of 2.1: a fall from a normal baseline argues against benign ethnic neutropenia and for a drug effect. Benign ethnic neutropenia should be documented before starting clozapine, not used retrospectively to explain a new drop.
Sepsis itself can cause neutropenia, but the temporal relationship to clozapine, the sore throat and the falling count make drug-induced agranulocytosis the leading concern. Do not restart clozapine without haematology advice; rechallenge after recovery is possible in selected patients but requires informed consent and close monitoring.
2. He plans to stop smoking next week. What is the pharmacokinetic consequence, how would you adjust treatment, and how do you manage his constipation?
Read the worked answer
Tobacco smoke contains polycyclic aromatic hydrocarbons that induce CYP1A2, the main enzyme metabolising clozapine. Stopping 30 cigarettes daily removes that induction, so clozapine levels can rise by roughly 30–70% within days to weeks, causing sedation, hypotension, hypersalivation, seizures and toxicity. Pre-emptively reduce the dose by about 20–30% (for example 300 mg to 225 mg) on the day he stops, check a trough level if available, and monitor for sedation, tachycardia, hypotension and seizures. The same adjustment is needed if he is hospitalised and cannot smoke. Nicotine replacement does not affect CYP1A2 and is safe, but monitor adherence. Caffeine intake and other inducers such as carbamazepine also matter.
Constipation: clozapine is strongly anticholinergic and has caused fatal ileus. Four days without a bowel movement requires active assessment for impaction, an osmotic laxative such as macrogol, a stimulant if needed, hydration and mobility. Every patient started on clozapine should receive a written bowel protocol. Avoid adding other anticholinergic drugs, and review him promptly if he develops abdominal pain, vomiting or distension.
3. What long-term monitoring does he need, and what would you do if clozapine had to be stopped permanently?
Read the worked answer
Monitoring: weight, waist, fasting glucose or HbA1c, lipids and BP at baseline, 3 months and then at least annually - clozapine carries the highest metabolic risk of any antipsychotic. Check CRP and troponin and do an ECG if myocarditis is suspected in the first 8 weeks; monitor for seizures, hypersalivation, sedation and constipation. Continue FBC monitoring according to the local clozapine protocol, and educate him to report fever, sore throat or mouth ulcers immediately.
If clozapine must stop: do not simply observe. He has treatment-resistant schizophrenia and relapse risk is high, with a marked increase in suicide risk after discontinuation. Options are rechallenge after haematological recovery with informed consent, or cross-taper to another agent - although he has already failed risperidone and olanzapine, so the evidence base is weak. Consider clozapine plus ECT, or a long-acting injectable antipsychotic with intensive psychosocial support. Document the haematological event, provide a patient card and register him with the monitoring service.
Smoking: make cessation a planned change with a clear date, a dose reduction and a level check rather than an unplanned stop, and involve the family in recognising early toxicity.